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Antimetastatic activity of a cyclooxygenase-2 inhibitor
G Roche-Nagle1, EM Connolly1, M Eng1, DJ Bouchier-Hayes1 and JH Harmey*,1
1Department of Surgery, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland
Cyclooxygenase-2 (COX-2) expression is increased in breast cancer and surgery has been shown to increase the growth of
metastatic tumours. We investigated the effect of selective COX-2 inhibition on the growth of metastases in either an experimental
metastasis model or following excision of a murine primary breast tumour. 50 000 4T1 mammary carcinoma cells were injected into
the mammary fat pad of female BALB/c mice. When the mean TD reached 870.4 mm, tumours were excised and the mice were
randomised into two groups (n¼ 12 per group) to receive daily intraperitoneal injections of the selective COX-2 inhibitor, SC-236 or
drug vehicle for 14 days. Alternatively, experimental metastases were established by tail-vein injection of 50 000 4T1 cells. Mice
received either the selective COX-2 inhibitor, SC-236 or drug vehicle for 14 days (n¼ 12 per group). SC-236 treatment significantly
reduced tumour burden, the number and size of spontaneous metastases following primary tumour excision. SC-236 treatment also
reduced tumour burden, the number and size of experimental metastases. Immunohistochemical staining demonstrated that COX-2
inhibition reduced microvessel density and increased apoptosis within both spontaneous and experimental metastases. These data
clearly demonstrate that the selective COX-2 inhibitor, SC-236, has potent antimetastatic activity against both spontaneous
metastases arising following primary tumour excision and experimental metastases.
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In most cancer patients, metastases are already present at time of
diagnosis (Fidler and Ellis, 1994) and while surgery remains the
mainstay of treatment for primary tumours it may paradoxically
enhance growth of residual or metastatic disease (Da Costa et al,
1998; Pidgeon et al, 1999; Demichelli et al, 2001). This may occur
as a consequence of an alteration in the balance between pro- and
antiangiogenic factors as part of the healing process and removal
of the tumour can of itself stimulate tumour growth by removing
the source of angiostatin (O’Reilly et al, 1997). There is an increase
in growth factors in the immediate postoperative period (Nissen
et al, 1998) and although angiogenesis is essential for wound
healing it also plays a key role in the growth and metastasis of
tumours (Folkman, 1997). In addition, surgical manipulation may
also increase tumour cell dissemination into the bloodstream
resulting in the seeding of tumour cells in distant organs and the
establishment of metastases (Fisher and Fisher, 1965; Hansen et al,
1995). As most cancer patients ultimately die of metastatic disease,
it is important to develop therapies that are effective against
metastases.
Several studies show that regularly taking aspirin or other
conventional nonsteroidal anti-inflammatory drugs (NSAIDs)
provides a 40– 50% reduction in the relative risk of death by
colon cancer, indicating that inhibition of cyclooxygenase (COX),
both COX-1 and COX-2, has a chemopreventive effect (Dubois
et al, 1998). In rodent models of Familial Adenomatous Polyposis
(FAP), a genetic disease leading to colon carcinoma, blockade of
COX-2, either by gene deletion or pharmacological inhibition of
enzyme activity, suppresses intestinal polyp formation (Oshima
et al, 2001). Cyclooxygenase-2 inhibition also demonstrates
chemopreventive activity against colon carcinogenesis in rodent
models (Reddy et al, 1996). NSAIDS inhibit the activity of both
COX enzymes and consequently can inhibit or abolish the effects
of prostaglandins (Bjorkman, 1998; Hawkey, 1999). Selective
inhibition of the COX-2 isoform has reduced toxicity profile
compared to inhibition of both isoforms (Scheiman, 2002). It has
been suggested that arachidonic acid, the substrate for COX-2,
induces apoptosis and that depletion of arachidonic acid by COX-2
activity decreases apoptosis (Cao et al, 2000). We previously
demonstrated that COX inhibition reduced the growth of a
primary tumour, number and incidence of spontaneous metastases
accompanied by increased apoptosis and decreased microvessel
density in the primary tumour (Connolly et al, 2002).
Prostaglandin E2 (PGE2), is produced in large amounts by some
tumours and has been implicated in the promotion and growth of
malignant tumours (Honn et al, 1981). PGE2 is produced from
arachidonic acid by either of two enzymes: COX-1 is expressed
constitutively in most tissues whereas COX-2 is predominantly
inducible but these classifications are not absolute. Cyclooxygen-
ase-2 is markedly increased at sites of inflammation and at sites of
proliferation such as within tumours (Hawkey, 1999) One of the
mechanisms by which PGE2 may support tumour growth is by
inducing angiogenesis necessary to supply oxygen and nutrients to
tumours (Form and Auerbach, 1983). Cyclooxygenase-2 expres-
sion has been observed in newly formed blood vessels within
tumours, whereas under normal physiological conditions the
quiescent vasculature expresses only the constitutive COX-1
enzyme (Masferrer et al, 1999).
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Growth, invasion and metastasis of many cancers depend on
angiogenesis (Folkman, 1990). The current view is that the net
balance between endogenous angiogenesis stimulators and in-
hibitors regulates the ‘switch to the angiogenic phenotype’
(Hanahan and Folkman, 1996). Vascular endothelial growth factor
(VEGF)/vascular permeability factor (VPF) is the most potent
angiogenic factor identified. VEGF induces both the migration and
proliferation of endothelial cells in vitro while inhibiting
endothelial cell apoptosis (Connolly et al, 1989). Therapeutic
blockade of VEGF has been shown to inhibit primary and
metastatic tumour growth in animal models (Kim et al, 1993;
Asano et al, 1995; Benjamin and Keshet 1997), which has been
attributed to an antiangiogenic effect. We and others have recently
shown that VEGF can also act as a survival factor for tumour cells,
protecting them from apoptosis (Pidgeon et al, 2001; Beierle et al,
2002; Harmey and Bouchier-Hayes, 2002a).
Although there are many studies showing that COX-2 inhibitors
have antitumour activity many of these have used chemically
induced tumours and there are few, if any, studies examining
antimetastatic effects of COX inhibition. We examined the
antimetastatic activity of COX-2 inhibitors in an orthotopic model
following excision of the primary tumour and in an experimental
metastasis model.
MATERIALS AND METHODS
Animals
Female 10–12-week-old BALB/c mice (Charles River Institute,
Margate, Kent, UK) were used. The animals were acclimatised for 1
week and caged in groups of five or less in an air-conditioned
room at ambient temperature of 21–221C and 50% humidity under
a 12-h light–dark cycle (lights at 0800). Animals were housed in a
licensed biomedical facility and all procedures were carried out
under animal license guidelines of the Department of Health,
Ireland and in accordance with the UK Co-ordinating Committee
on Cancer Research (UKCCCR) Guidelines for the Welfare of
Animals in Experimental Neoplasia (Workman et al, 1998).
Animals had ad libitum access to animal chow (WM Connolly &
Sons Ltd, Kilkenny, Ireland) and water.
Tumour cells and culture conditions
4T1 tumour cells, a spontaneously metastasising mammary
adenocarcinoma cell line were a generous gift from Dr Fred
Miller, Duke University. Cells were maintained as monolayer
cultures in Dulbecco’s modified Eagle medium supplemented with
10% foetal bovine serum (FBS), sodium pyruvate and L-glutamine
(Life Technologies, Inc., GIBCO BRL, Paisley, UK). Cell cultures
were incubated in an atmosphere of 5% CO2 in air at 371C.
Tumour cells were harvested from subconfluent cultures with
0.25% trypsin-0.02% EDTA. Trypsin was neutralised with medium
containing 10% FBS, washed three times in phosphate-buffered
saline (PBS) and resuspended in PBS at 5 105 ml1 for injection.
Only single cell suspensions of greater than 90% viability as
determined by trypan blue exclusion were used for injections.
Experimental design
4T1 cells (5 104) were injected into the mammary fat pad behind
the left forefoot after anaesthesia was induced and maintained with
inhalational halothane. Primary tumours were measured on
alternate days following injection of tumour cells using a Vernier
calipers. Tumour diameter (TD) was calculated as the square root
of the product of two perpendicular diameters (Pulaski and
Ostrand-Rosenberg, 1998). When mean TD was 8.070.4 mm (day
14 postinjection of tumour cells), primary tumours were excised.
They were then randomised into one of two groups (n¼ 12 per
group). The treatment and control groups received daily
intraperitoneal injections of either 200 ml of the selective COX-2
inhibitor, SC-236 (6 mg kg1 in 1% v v1 dimethylsulphoxide
DMSO) or vehicle (1% DMSO), respectively, for 14 days. Animals
were killed and lungs excised. Lungs from seven mice per group
were fixed in Bouins solution and the number and size of lung
lesions determined with the aid of a dissecting microscope (Yano
et al, 2000). Lungs from remaining five mice per group were
processed for immunohistochemistry.
For studies on experimental metastases BALB/c mice (n¼ 12 per
group) received 5 104 4T1 cells via tail-vein injection. Controls
received daily intraperitoneal injections of 200ml drug vehicle (1%
DMSO) while the treatment group received SC-236 by intraper-
itoneal injection (6 mg kg1 in 1% DMSO) starting on the day of
tumour cell injection. After 14 days, mice were killed, lungs
removed, fixed in Bouins solution and the number and size of lung
lesions determined as above (n¼ 7). Lungs from remaining five
mice per group were processed for immunohistochemistry. All
experiments were performed in duplicate.
Serum collection
At the time of killing, animals were anaesthesised with halothane
and their chests cleaned with ethanol. Blood was obtained via a
closed cardiac puncture by means of a 22-gauge hypodermic
needle and a subxiphoid approach. Blood was allowed to clot for
2 h at room temperature and centrifuged for 20 min at 1100 g.
Serum was removed, filtered through a 0.22 mm filter and stored at
801C. VEGF was measured by enzyme-linked immunosorbent
assay (ELISA) according to the manufacturer’s instructions (R&D
Systems, Oxford, UK).
Quantification of microvessel density
Harvested lungs (n¼ 5) were embedded in OCT compound (Miles
Inc., Elkhart, IN, USA), snap frozen in liquid nitrogen and stored
at 801C. Microvessel density was determined as described
previously by staining with MECA 32 antibody (rat anti-mouse
panendothelial antigen (Pharmingen, CA, USA)) (Harmey et al,
2002b). For each section, vessels were counted in three high-power
fields ( 200 magnification ( 20 objective and  10 ocular)) as
described. Lung sections from each of five mice per group were
analysed. Data are expressed as mean7s.e.m.
Tumour apoptosis
Harvested lungs were embedded in OCT compound (Miles Inc.,
Elkhart, IN, USA), snap frozen in liquid nitrogen and stored
at 801C. Sections (8 mm) were fixed in cold acetone for 5 min,
1 : 1 acetone : chloroform for 5 min, acetone for 5 min and
washed 3 times in phosphate-buffered saline (PBS) for 5 min each.
Apoptotic cells within tumour metastases were stained using the in
situ cell death detection kit according to the manufacturer’s
instructions (Boehringer Mannheim, East Sussex, UK). Peroxidase
activity was visualised by the precipitation of 3,30-diaminobenzi-
dene (DAB) and sections were lightly counterstained with
haematoxylin. Apoptotic cells stained brown against a blue
background. Only cells which stained brown and had the
morphological appearance of an apoptotic cell were counted as
apoptotic cells, necrotic cells were easily distinguished and were
excluded. Apoptosis was expressed as the number of apoptotic
cells in three high-power fields per section ( 400 magnifica-
tion ( 40 objective and  10 ocular)). Lung sections from each of
five mice per group were analysed. Data are expressed as
mean7s.e.m.
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Statistical analysis
Data are expressed as mean7standard error mean (s.e.m.).
Differences between treatment groups were determined by
unpaired t-test using Instat for Windows statistics package
(Graphpad Software Inc). Data were taken as significant where
Po0.05.
RESULTS
Effect of COX-2 inhibition on metastases
We previously demonstrated that COX-2 inhibition decreased the
number of metastases from a primary mammary fat pad 4T1
tumour in situ (Connolly et al, 2002). However, in that study, the
observed reduction in metastases could simply have reflected the
decreased primary tumour size in mice treated with COX-2
inhibitor rather than a direct effect on the metastases. To clarify
the issue, we examined the antimetastatic activity of COX-2
inhibitor following excision of a primary mammary fat pad tumour
and in an experimental metastasis model where 4TI tumour cells
were injected intravenously.
4T1 mammary adenocarcinoma cells spontaneously metastasise
to the lungs from the mammary fat pad (Pulaski and Ostrand-
Rosenberg, 1998). Mammary fat pad tumours were excised when
they reached a TD of 870.4 mm and mice were given SC-236 daily
for 14 days after the tumours were excised. SC-236 treatment
resulted in a significant reduction in both the number and size of
spontaneous lung metastases relative to untreated controls
(Table 1). The median number of spontaneous pulmonary
metastases was 22.5 (14–57) in the control group, and 6 (3–34)
in the SC-236-treated group (P¼ 0.04). The lung nodules in the
control group were also significantly larger than those in the SC-
236-treated mice (median diameter 0.98 (0.81 –1.1) mm vs 0.76
(0.64–0.87) mm, P¼ 0.002). Excised lungs were weighed and
metastatic burden expressed as lung-to-body ratio as before
(Pidgeon et al, 1999). The COX-2-treated mice showed a significant
decrease in tumour burden (0.8670.2) as compared with controls
(1.170.16) (P¼ 0.01).
To confirm the antimetastatic effect of COX-2 inhibition an
experimental metastasis model was used. 4T1 tumour cells were
injected via lateral tail vein and COX-2 inhibitor was administered
daily for 14 days. SC-236 treatment resulted in significantly fewer
metastases than in control mice (33 (17–40) vs 97 (67–135)
(P¼ 0.02). Furthermore, the size of metatases in the control group
were also significantly larger than those in the SC-236-treated mice
(median diameter 0.77 (0.33–0.99) vs 0.65 (0.18 –0.79) mm,
P¼ 0.046). (Table 2)
Effect of COX-2 inhibition on apoptosis within the lung
metastases
The selective COX-2 inhibitor, SC-236, demonstrated antimeta-
static activity against both experimental metastases and sponta-
neous metastases arising following excision of a primary tumour.
The relative levels of apoptosis and proliferation determine net
tumour growth (Holmgren et al, 1995). In our previous studies,
although SC-236 treatment had no effect on proliferation within
4T1 primary tumours, it significantly increased tumour cell
apoptosis (Connolly et al, 2002). We investigated whether the
reduction in number and size of metastases following SC-236
treatment was due to increased apoptosis within the metastases.
Apoptotic cells were identified by TUNEL staining and represen-
tative sections are shown in Figure 1A. SC-236 treatment following
primary tumour excision resulted in a significant increase in the
level of apoptosis within metastases (2.370.5 TUNEL-positive
cells/h.p.f.) relative to control tumours (0.6770.08 TUNEL-
positive cells/h.p.f.) (P¼ 0.006) (Figure 1B). This increased
apoptosis was also evident in SC-236-treated mice in the
experimental metastasis model (1.4670.12 TUNEL-positive cells/
h.p.f.) relative to untreated controls (0.6470.07 TUNEL-positive
cells/h.p.f.) (P¼ 0.006) (Figure 1C).
COX inhibition reduces tumour angiogenesis
To further investigate the mechanisms by which the selective COX-
2 inhibitor (SC-236) reduced metastasis, we examined the effect of
treatment on angiogenesis within the pulmonary metastases
following excision of primary tumour. Vascularisation was
identified by staining tumours with MECA-32 antibody
(Figure 2A) and the number of vessels/high-power field scored.
Treatment with SC-236 significantly reduced angiogenesis in the
pulmonary metastases (1672.2 vessels/h.p.f.), relative to controls
(2774 vessels/h.p.f.) (Po0.05) (Figure 2B). The reduction in
angiogenesis within metastases was relected in the serum levels of
VEGF. Treatment with SC-236 following excision of primary
tumour significantly reduced circulating VEGF (30.576 pg ml1)
relative to controls (83.5720.9 pg ml1) (P¼ 0.02). The antiangio-
genic effect of SC-236 treatment was also evident in the
experimental metastasis model (12.871.8 vessels/h.p.f. in SC-236
treated mice compared to 22.772.9 vessels/h.p.f. in controls.
(P¼ 0.017). Figure 2C. As in the spontaneous metastasis model,
treatment with SC-236 significantly reduced circulating VEGF
relative to controls (37.6717.2 vs 93.2755.3 pg ml1) (P¼ 0.017).
DISCUSSION
While surgery results in the successful removal of the primary
tumour in the majority of patients, a significant number of patients
Table 1 Effect of selective COX-2 inhibition (SC-236) on metastasis
following excision of a 4TI mammary fat pad primary tumour
Metastatic
burden (lung
wt/body wt)
Incidence of
pulmonary
metastasis
Number of
pulmonary
nodules
Diameter of
nodules (mm)
n¼ 12 n¼ 12 n¼ 7 n¼ 7
Control 1.0570.05 12/12 22.5 (14–57) 0.98 (0.81–1.1)
SC-236 0.8670.05a 12/12 6 (3–34)b 0.76 (0.64–0.87)c
4T1 cells (5 104) were injected into the mammary fat pad of BALB/c female mice
and tumour excised when mean diameter was 870.4 mm. Following excision daily
intraperitoneal injections of vehicle or SC-236 began and continued for 14 days. The
animals were killed. The number, size and incidence of pulmonary nodules were
recorded. Lung-to-body weight ratio was calculated as a measure of metastatic
burden. Data are shown as mean7s.e.m. with nodule data as median (range). Data
were analysed by using unpaired t-test, aPo0.01 vs control, bPo0.04 vs control,
cPo0.002 vs control.
Table 2 Effect of selective COX-2 inhibition (SC-236) on experimental
metastasis
Metastatic
burden (lung
wt/body wt)
Incidence of
pulmonary
metastasis
Number of
pulmonary
nodules
Diameter of
nodules (mm)
n¼ 12 n¼ 12 n¼ 7 n¼ 7
Control 0.970.16 12/12 97 (67–135) 0.77 (0.33–0.99)
SC-236 0.6670.05a 12/12 33 (17–40)b 0.65 (0.18–0.79)c
BALB/c female mice were injected with 5 104 4T1 cells via tail vein followed by
daily intraperitoneal injections of vehicle or SC-236 for 14 days. The number, size and
incidence of pulmonary nodules were recorded. Lung-to-body weight ratio was
calculated as a measure of metastatic burden. Data are shown as mean7s.e.m. with
nodule data as median (range). Data were analysed by using unpaired t-test, aPo0.02
vs control, bPo0.02 vs control, cPo0.05 vs control.
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subsequently die of metastatic disease. The release of proangio-
genic factors in the postoperative period may contribute to the
growth of previously dormant metastases. In addition, removal
of the primary tumour, a source of the endogenous angio-
genesis inhibitor, angiostatin, may remove a ‘brake’ on metastatic
growth (O’Reilly et al, 1997). Previously, we have shown that the
surgical insult accelerates the growth of the primary tumour and
increases pulmonary metastases (Da Costa et al, 1998; Pidgeon
et al, 1999).
4TI cells originated from a spontaneously occurring BALB/c
mouse breast tumour and share many characteristics with human
mammary cancers (Pulaski and Ostrand-Rosenberg, 1998). In our
previous studies, it was unclear whether decreased metastatic
growth in response to COX-2 inhibition was a direct effect on
metastases or simply a reflection of decreased primary tumour size
(Connolly et al, 2002). Here, we used two metastatic models, one
where 4T1 cells were injected via tail vein, a model which is limited
by the tumour cells arriving in the lungs as part of a first flow
phenomenon bypassing the liver. In the second spontaneous
metastasis model, a primary tumour was excised. The second is a
more clinically relevant orthotopic model of breast cancer, where
the primary tumour was excised. Using this orthotopic model of
breast cancer excision, we found a highly significant reduction in
both the size and number of spontaneous lung metastases in
animals receiving daily injections of the selective COX-2 inhibitor,
SC-236, postexcision. Furthermore, SC-236 decreased metastatic
growth in the experimental metastasis model. These studies clearly
demonstrate that the COX-2 inhibitor, SC-236, has a direct
antimetastatic effect.
High levels of apoptosis within breast tumours undergoing
chemotherapy have been shown to predict a favourable response
to treatment (Chang et al, 2000). NSAIDS can induce cells to
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Figure 1 Apoptosis in spontaneous and experimental lung metastases. (A) Representative sections showing TUNEL-positive cells. Original
magnification 400. (B) Number of TUNEL-positive cells per high-power field ( 400 magnification ( 40 objective and  10 ocular)) (three high-power
fields per section). SC-236 significantly increased apoptosis within spontaneous metastases relative to control mice (one section from each of five mice per
group). Data represented as mean7s.e.m. * P¼ 0.006 (n¼ 5). (C) In experimental metastases SC-236 also significantly increased apoptosis. Data
represented as mean7s.e.m. * P¼ 0.006 (n¼ 5).
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undergo apoptosis in vitro (Lu et al, 1995). Arachidonic acid
stimulates apoptosis, therefore COX-2 inhibition could induce
apoptosis by decreasing the conversion of arachidonic acid to
prostaglandins (Cao et al, 2000). In addition, selective COX-2
inhibition has been shown to induce apoptosis through a
cytochrome C-dependent pathway in oesophageal cancer cells (Li
et al, 2001). Other studies have examined the effects of COX
inhibitors on behaviour of tumour cells in vitro. These data
indicate that these same drugs can limit growth of cultured
mammary tumour cells, induce cell cycle arrest and increase
intracellular ceramide levels (Kundu et al, 2001). Clearly, more
studies are needed to discern the mechanisms responsible for the
antitumour and antimetastatic effects of these drugs. We found
that COX-2 inhibition increased tumour cell apoptosis within lung
metastases relative to control in both the spontaneous and
experimental metastasis models.
Microvessel density within the primary tumour, a measure of
the degree of angiogenesis, is an independent predictor of
metastatic disease in breast cancer patients (Weidner et al,
1991). COX-2 inhibitors have been shown to reduce angiogenesis
in vitro (Tsujii et al, 1998) and in vivo (Masferrer 2001). Williams
et al (2000), found reduced angiogenesis in Lewis lung carcinomas
grown in COX-2 knockout (COX-2/) mice when compared to
tumours grown in wild-type mice. Here, we show that COX-2
inhibition also decreases angiogenesis within spontaneous and
experimental metastases suggesting that in addition to increasing
tumour cell apoptosis these drugs exert their antimetastatic effect
by also reducing angiogenesis in the metastases. Our hypothesis is
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Figure 2 Angiogenesis in spontaneous and experimental lung metastases. (A) Representative sections stained for meca-32. Original magnification 400.
(B) Microvessel density was assessed by light microscopy following meca-32 staining (one section from each of five mice per group). For each section,
vessels were counted in three high-power fields ( 400 magnification ( 40 objective and  10 ocular)). SC-236 significantly decreased microvessel density
within spontaneous metastases relative to control mice. Data are expressed as mean number of vessels/h.p.f.7s.e.m. *Po0.05 vs control. (C) In
experimental metastases SC-236 also significantly decreased microvessel density. Data represented as mean7s.e.m. *Po0.02 (n¼ 5).
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further supported by studies indicating a role for COX-2 in the
production of angiogenic factors by cancer cells (Tsujii et al, 1998),
increased cell proliferation (Sheng et al, 1988), prevention of
apoptosis (Tsujii and DuBois, 1995), increased metastatic potential
(Tsujii et al, 1997) and the inhibition of immune surveillance
(Huang et al, 1998).
In addition to inhibiting tumour growth via COX inhibition, it is
possible that COX-2 inhibitors may also effect other target
molecules. There are studies which show that NSAIDs can have
COX-independent activity. First, there is no correlation between
sensitivity to NSAID-induced cell death and levels of COX
expression in transformed fibroblasts derived from COX-2/,
COX-1/, or COX-1//COX-2/ mice (Zhang et al, 1999). In
addition, NSAID derivatives without COX-inhibitory activity, such
as sulindac sulphine, can inhibit chemically induced colon
carcinogenesis without affecting prostaglandin levels. (Piazza
et al, 1997). Moreover, high doses of NSAIDs induce apoptosis
in colorectal cancer cells with no detectable COX-1 or COX-2
activity (Hanif et al, 1996; Williams et al, 2000). Several alternative
targets have been proposed to explain COX-independent effects of
NSAIDs. High doses of ASA (aminosalicylic acid) have been shown
to antagonise the NF-kB signalling pathway (Koop and Ghosh,
1994). Peroxisome proliferator-activated receptors (PPARs) are
ligand-inducible transcription factors, which belong to the nuclear
hormone receptor superfamily. Three different isoforms, PPARa, d
and g have been identified in humans, each with a different pattern
of expression. Fatty acids and certain fatty acid metabolites
have been suggested as endogenous ligands for these receptors.
Indomethacin can bind to, and induce transcriptional activity of
PPARa and g isoforms, and PPARd is a target for sulindac
(Lehmann et al, 1997; He et al, 1999). Finally, NSAIDs decrease
levels of the antiapoptotic protein, Bcl-XL (Zhang et al, 2000). In
general, COX-independent effects of NSAIDs require higher
concentrations than COX-dependent effects. The concentration
of Celecoxib, required to induce apoptosis in vitro is in the 50–
100mM range (Williams et al, 2000a). This is 10–200-fold higher
than serum concentrations required to inhibit tumour growth in
mouse models for colorectal and breast cancer (Jacoby et al, 2000;
Williams et al, 2000a). At low concentrations, the best-charac-
terised targets of NSAIDs remain the COX enzymes. (Gupta and
Dubois, 2001).
In summary, we have clearly demonstrated that COX-2
inhibitors have a potent antimetastatic effect increasing apoptosis
and decreasing angiogenesis within both spontaneous and
experimental metastases. The selective COX-2 inhibitors are in
everyday clinical use, cheap and with a known side effect-profile.
Our data suggest that COX-2 inhibitors may have clinical utility in
the management of metastatic disease especially in the periopera-
tive period.
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